Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
Major study of women with either inactive or stable systemic lupus erythematosus (lupus) – a disease in which the body's immune system mistakenly attacks and damages healthy tissues of the skin, joints and internal organs – were able to take oral contraceptives without increased risk of flares, or periods of increased disease activity, that characterize the disease.
Researchers at Wake Forest University School of Medicine and the University of Virginia hope to reset part of the "epigenetic code" in lupus patients and thus improve treatment.
The investigators published their findings in the August issue of Immunity. "We think this study will open a new area of research in understanding how our immune systems protect us," says Weissman.
Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.
A report by Yale scientists in the journal Cell sheds new light on how the protein Ro, a major autoantigen in patients with autoimmune disease, recognizes misfolded RNAs, creating a RNA quality control system for cells.
La Jolla Pharmaceutical Company today announced that it has received "fast track" designation for Riquent (abetimus sodium) for the treatment of lupus renal disease from the U.S. Food and Drug Administration (FDA).
A new gene suspected to contribute to autoimmune diseases such as type 1 diabetes and lupus - a condition in which the body’s own immune system attacks organs such as the kidneys and skin - has been discovered by Australian National University (ANU) immunologists.
In findings that could have implications for autoimmune disorders and drug-resistant bacterial infections, researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key protein involved in the appropriate shut-down of inflammation following an immune response to invading pathogens.
Almost everyone has been infected with Epstein-Barr virus (EBV), a member of the herpes family and one of the most common human viruses.
Aggressive therapy with statins -- drugs that inhibit cholesterol synthesis -- works better than moderate statin therapy in reducing fats and proteins in the blood that have been linked to atherosclerosis, a new multi-center study concludes. Statins’ effects on both complex compounds appear beneficial in cutting patients’ cardiovascular risks.
MedImmune and Medarex have announced a collaboration to develop antibodies targeting interferon-alpha and the type I interferon receptor 1.
University of Pittsburgh researchers have identified biomarkers that could result in earlier and more accurate diagnosis of systemic lupus erythematosus (SLE), a devastating disease that affects as many as 1.5 million Americans, and occurs 10 to 15 times more frequently in women.
Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, found no convincing evidence that breast implants have an effect on the development of subsequent connective tissue disorders (CTDs).
Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in “Nature Immunology.”
It is estimated that between 1.5 million and 2 million women in this country have had breast implants since they first appeared on the market in 1962.
Researchers at the University of Minnesota have identified, for the first time, a gene variation associated with systemic lupus erythematosus (SLE), a potentially fatal disease which causes the body's defence system to attack itself.
A mysterious disease that causes the body’s immune system to turn against itself also sends a warning signal to alert doctors of the onset of its worst symptoms, University of Florida physicians have found.
The study will include a basic research component to examine the roles of B and T cells, white blood cells in the immune system, in triggering lupus symptoms.
The S.L.E. Lupus Foundation believes that significantly raising awareness about lupus, both among women who may be at risk, as well as physicians, whose accurate diagnosis could be a matter of life or death, is critical.